INT79270
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
We therefore do not believe that HRT status had any significant impact on our results, namely a lack of correlation between mammographic density and Ki-67 expression. | |||||||||||||||
| |||||||||||||||
|
Median level of Ki-67 expression was 1.9% (range 0% to 33%). | |||||||||||||||
| |||||||||||||||
|
We have previously shown that Ki-67 expression in benign epithelial cells is positively correlated with epithelial cell number and cytomorphologic abnormality in women at increased risk for breast cancer [6]. | |||||||||||||||
| |||||||||||||||
|
The techniques of immediate per-operative in vitro labelling with bromodeoxyuridine (BrdU) and conventional immunohistochemistry for Ki-67 antigen expression were used to identify proliferating cells. | |||||||||||||||
| |||||||||||||||
|
Immunohistochemistry showed expression of p53 oncoprotein and Ki-67 antigen in the carcinoma cells. | |||||||||||||||
| |||||||||||||||
|
Ki-67 expression is currently being used in phase II breast cancer chemoprevention trials. | |||||||||||||||
| |||||||||||||||
|
In a recently reported study, Ki-67 (MIB-1) expression was assessed in areas of low, medium, and high mammographic density in benign breast tissue obtained from reduction mammoplasties. | |||||||||||||||
| |||||||||||||||
|
Ki-67 expression in benign breast cells obtained from RPFNA is also a reversible, a potential risk and a possible surrogate response biomarker. | |||||||||||||||
| |||||||||||||||
|
In a cohort of 147 high risk women, we previously showed that cytomorphologic atypia in benign breast cells obtained by RPFNA is associated with increased Ki-67 expression [6]. | |||||||||||||||
| |||||||||||||||
|
Contrary to what might be expected, Ki-67 expression in epithelial cells was less in the areas of medium and high density as compared with the areas of low density [32]. | |||||||||||||||
| |||||||||||||||
|
Ki-67 expression was greater in specimens exhibiting cytomorphologic atypia (P = 0.01) and greater cellularity (P = 0.001; Table 2).
| |||||||||||||||
| |||||||||||||||
|
Median Ki-67 expression was 2.8% in women with RPFNA atypia as compared with 1.1% in women without atypia. | |||||||||||||||
| |||||||||||||||
|
There was no difference in Ki-67 expression between specimens from postmenopausal women receiving HRT and specimens from those who were not on HRT, but only 21% of women on HRT were on estrogen plus a progestin. | |||||||||||||||
| |||||||||||||||
|
Ki-67 expression | |||||||||||||||
| |||||||||||||||
|
After the antigen retrieval in a hot water bath, the prediluted monoclonal anti-Ki67 antibody (Biogenex, San Ramon, USA) was incubated for 30 min; antibody demonstration was performed with the commercially available anti-mouse IgG detection kit (EnVision, DakoCytomation). | |||||||||||||||
| |||||||||||||||
|
Our findings indicate that mammographic density, cytomorphology, and Ki-67 expression are independent variables, and may be complementary when used as risk predictors or response biomarkers in breast cancer chemoprevention trials. | |||||||||||||||
| |||||||||||||||
|
Given the lack of correlation of mammographic breast density with either cytomorphology or Ki-67 expression in RPFNA specimens, mammographic density and Ki-67 expression should be considered as potentially complementary response biomarkers in breast cancer chemoprevention trials.
| |||||||||||||||
| |||||||||||||||
|
Furthermore, our results continue to show that Ki-67 expression is associated with the risk biomarker cytomorphology in high-risk women, and thus they provide evidence that Ki-67 may be used as a response biomarker in proof-of-principle phase II trials.
| |||||||||||||||
| |||||||||||||||
|
We previously showed that Ki-67 expression is higher in specimens of benign breast cells exhibiting cytologic atypia that are obtained by random periareolar fine needle aspiration (RPFNA). | |||||||||||||||
| |||||||||||||||
|
The overall expression of Ki67 antigen (dilution 1:200; DAKO, Glostrup/Denmark) was low, but some foci with an index of 30% were identified. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.